IOVANCE BIOTHERAPEUTICS Files 8-K for 'Other Events' & Exhibits

Ticker: IOVA · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1425205

Iovance Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyIovance Biotherapeutics, Inc. (IOVA)
Form Type8-K
Filed DateJan 8, 2024
Risk Levelmedium
Pages1
Reading Time2 min
Key Dollar Amounts$0.000041666
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-action, regulatory-filing, other-events

TL;DR

**IOVANCE filed an 8-K for 'Other Events' and exhibits, signaling big news is coming.**

AI Summary

IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K on January 8, 2024, indicating that it is using this filing for 'Other Events' and 'Financial Statements and Exhibits'. The company, based in San Carlos, California, with a business phone of (650) 260-7120, is leveraging this filing to satisfy obligations under Rule 425, Rule 14a-12, Rule 14d-2(b), and Rule 13e-4(c). This matters to investors because it signals that the company is likely communicating important information related to a potential offering, merger, or other significant corporate action that could impact share value.

Why It Matters

This filing suggests IOVANCE BIOTHERAPEUTICS is preparing to disclose significant corporate news, potentially related to a new stock offering, a merger, or other material developments that could affect its stock price.

Risk Assessment

Risk Level: medium — The 'Other Events' item on an 8-K can cover a wide range of significant, but unspecified, corporate actions, introducing uncertainty for investors.

Analyst Insight

Investors should monitor IOVANCE BIOTHERAPEUTICS for subsequent filings or press releases that will clarify the 'Other Events' mentioned in this 8-K, as it likely precedes significant corporate news.

Key Players & Entities

  • IOVANCE BIOTHERAPEUTICS, INC. (company) — the registrant filing the 8-K
  • January 8, 2024 (date) — date of earliest event reported and filing date
  • San Carlos, California (location) — address of principal executive offices
  • 001-36860 (other) — Commission File Number
  • 75-3254381 (other) — I.R.S. Employer Identification No.
  • (650) 260-7120 (other) — Registrant’s Telephone Number

FAQ

What is the primary purpose of IOVANCE BIOTHERAPEUTICS, INC.'s 8-K filing on January 8, 2024?

The primary purpose of IOVANCE BIOTHERAPEUTICS, INC.'s 8-K filing on January 8, 2024, is to report 'Other Events' and 'Financial Statements and Exhibits' as per the Item Information section of the filing.

Under which specific SEC rules is IOVANCE BIOTHERAPEUTICS, INC. simultaneously satisfying filing obligations with this 8-K?

IOVANCE BIOTHERAPEUTICS, INC. is simultaneously satisfying filing obligations under Rule 425 (17 CFR 230.425), Rule 14a-12 (17 CFR 240.14a-12), Rule 14d-2(b) (17 CFR 240.14d-2(b)), and Rule 13e-4(c) (17 CFR 240.13e-4(c)), as indicated by the checked boxes in the filing.

What is the state of incorporation for IOVANCE BIOTHERAPEUTICS, INC.?

IOVANCE BIOTHERAPEUTICS, INC. is incorporated in Delaware, as stated in the 'State of Incorporation' field.

What is the business address of IOVANCE BIOTHERAPEUTICS, INC. as listed in the filing?

The business address of IOVANCE BIOTHERAPEUTICS, INC. is 825 Industrial Road, Suite 400, San Carlos, California, 94070, according to the 'Address of Principal Executive Offices' section.

What is the Central Index Key (CIK) for IOVANCE BIOTHERAPEUTICS, INC.?

The Central Index Key (CIK) for IOVANCE BIOTHERAPEUTICS, INC. is 0001425205, as listed under 'COMPANY DATA' in the filing.

Filing Stats: 434 words · 2 min read · ~1 pages · Grade level 9.7 · Accepted 2024-01-08 17:03:09

Key Financial Figures

  • $0.000041666 — h registered Common stock, par value $0.000041666 per value IOVA The Nasdaq Stock Marke

Filing Documents

01

Item 8.01 Other Events. On January 8, 2024, Iovance Biotherapeutics, Inc. (the "Company") updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company's presentation that it intends to use at such events, including the J.P. Morgan Healthcare Conference, is attached as Exhibit 99.1 and incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Iovance Biotherapeutics, Inc., Corporate Presentation - January 2024 104 Cover Page Interactive Data File (embedded as Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 IOVANCE BIOTHERAPEUTICS, INC. By: /s/ Frederick G. Vogt Frederick G. Vogt, Interim CEO & General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.